Qima Life Sciences gives an oral presentation entitled “IL-15 contributes to atopic dermatitis pathogenesis: lessons from a novel humanized mouse disease model”. In this model, CALY-002 anti-IL-15 antibody demonstrated efficacy across multiple clinical, histological and immunological endpoints. ...
Jos Houbiers, CMO of Calypso Biotech, gives an oral presentation entitled: “Interim resuts from a first-in-human study of the anti-IL-15 antibody CALY-002 for treating Celiac Disease and Eosinophilic Esophagitis”. ...
Calypso Biotech and Qima Life Sciences presents a poster entitled “IL-15 contributes to atopic dermatitis pathogenesis: lessons from a novel humanized mouse disease model”. In this model, CALY-002 anti-IL-15 antibody demonstrated efficacy across multiple clinical, histological and immunological endpoints. ...
19th International Celiac Disease Symposium, Sorrento, Italy. Jos Houbiers, Chief Medical Officer of calypso Biotech, gives a lecture entitled “Interim results from an in-human study of an anti-IL-15 antibody for treating celiac disease” ...
51st European Society for Dermatological Research meeting, Amsterdam, the Netherlands. Calypso Biotech and Monasterium present a poster entitled “Interleukin-15 inhibition ameliorates atopic dermatitis lesions experimentally induced in xenotransplanted human skin” ...
EUREOS is the European association for clinicians and researchers to share knowledge on Eosinophilic Esophagitis. http://eureos.online...
Click to see full press release...